Magnolol, A Novel Antagonist of Thrombin and PAR-1, Inhibits Thrombin-Induced Connective Tissue Growth Factor (CTGF) Expression in Vascular Smooth Muscle Cells and Ameliorate Pathogenesis of Restenosis in Rats

Resumen

Treatment of magnolol represents a new therapeutic strategy that may reduce the risk of vascular diseases associated with abnormal vascular smooth muscle cell (VSMC) migration or thrombin/protease-activated receptor 1 (PAR-1) activation.